On Monday Prime Medicine Inc (NASDAQ: PRME) opened higher 2.07% from the last session, before settling in for the closing price of $2.42. Price fluctuations for PRME have ranged from $1.11 to $6.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -124.13% over the last five years. Company’s average yearly earnings per share was noted 23.33% at the time writing. With a float of $51.66 million, this company’s outstanding shares have now reached $131.16 million.
The firm has a total of 214 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.87%, operating margin of -496.2%, and the pretax margin is -485.69%.
Prime Medicine Inc (PRME) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Prime Medicine Inc is 60.65%, while institutional ownership is 28.66%. The most recent insider transaction that took place on Jun 23 ’25, was worth 45,402. In this transaction 10% Owner of this company bought 21,000 shares at a rate of $2.16, taking the stock ownership to the 20,219,945 shares. Before that another transaction happened on Jun 16 ’25, when Company’s 10% Owner bought 21,000 for $1.49, making the entire transaction worth $31,196. This insider now owns 20,198,945 shares in total.
Prime Medicine Inc (PRME) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.30% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Check out the current performance indicators for Prime Medicine Inc (PRME). In the past quarter, the stock posted a quick ratio of 4.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 84.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Analysing the last 5-days average volume posted by the [Prime Medicine Inc, PRME], we can find that recorded value of 4.29 million was better than the volume posted last year of 1.79 million. As of the previous 9 days, the stock’s Stochastic %D was 82.54%.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 60.44%, which indicates a significant decrease from 77.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 110.97% in the past 14 days, which was lower than the 123.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.58, while its 200-day Moving Average is $2.63. Now, the first resistance to watch is $2.64. This is followed by the second major resistance level at $2.80. The third major resistance level sits at $2.92. If the price goes on to break the first support level at $2.36, it is likely to go to the next support level at $2.24. Should the price break the second support level, the third support level stands at $2.08.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are currently 131,294K shares outstanding in the company with a market cap of 324.30 million. Presently, the company’s annual sales total 2,980 K according to its annual income of -195,880 K. Last quarter, the company’s sales amounted to 1,450 K and its income totaled -51,890 K.
